lipolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Isotopes are commonly used to determine the concentration of various elements or substances using the isotope dilution method, whereby known amounts of isotopically substituted compounds are mixed with the samples and the isotopic signatures of the resulting mixtures are determined with mass spectrometry.
== Subsidiaries & Joint ventures == Jupiter Electric Mobility: Jupiter Electric Mobility (JEM) is a fully owned subsidiary of Jupiter Wagons Limited. It launched two Electric Light Commercial Vehicles (eLCV) at Auto Expo 2023 in Greater Noida. JEM TEZ is a smaller truck with up to 1 ton payload, and EV Star CC will be capable of carrying heavier payload. EV Star CC vehicle will be brought to Indian market in technical collaboration with EA GreenPower Motors, Canada. JEM TEZ is an indigenously developed vehicle and will be manufactured in its Indore plant. JEM Tez is expected to enter Indian market in 2024.JEM announced a landmark acquisition of Log9’s technology and business assets for its Railway Battery and Electric Truck Battery Divisions. JWL CAF Joint Venture: JWL entered into a MoU with Spain based firm CAF for setting up a manufacturing facility at an estimated investment of around ₹300crore. The investment as per plan would to be jointly funded by JWL and CAF. JWL DAKO-CZ India Limited: In 2022 JWL DAKO-CZ India Ltd was established to focus on development and supply of complete and modern braking system for the Indian Railways. JWL Talegria India Pvt. Ltd.: JWL has formed a JV with Talleres Alegria of Spain and has started the trials for Flash-butt welded CMS Crossings for Indian railways and global market. JWL Kovis India Pvt. Ltd.: JWL has formed a JV with Kovis d.o.o. of Slovenia and has started the manufacturing of Brake disc for high-speed passenger coaches in its Richai, Jabalpur plant.
early production of insulin for treatment of Australian diabetics (1923) development of a tetanus vaccine (1938) development of a combined vaccine for diphtheria, tetanus and whooping cough (1953) rapid adoption and production of a polio vaccine (1956) development of a multi-purpose animal vaccine covering pulpy kidney (enterotoxemia), tetanus, black disease, malignant oedema and blackleg (1961) production of Rhesus (D) immunoglobulin to prevent haemolytic disease in newborns due to Rh factor incompatibility (1966–67) pioneering heat treatment to protect blood and plasma products from infection with HIV (1983) collaboration on development of the world's first human papillomavirus vaccine, Gardasil, building on the pioneering work by Professor Ian Frazer (1994–2005).
Sources: en.wikipedia.org
=== Industrial applications === Formaldehyde is a common precursor to more complex compounds and materials. In approximate order of decreasing consumption, products generated from formaldehyde include urea formaldehyde resin, melamine resin, phenol formaldehyde resin, polyoxymethylene plastics, 1,4-butanediol, and methylene diphenyl diisocyanate. The textile industry uses formaldehyde-based resins as finishers to make fabrics crease-resistant.
Soybeans and processed soy foods are among the richest foods in total phytoestrogens (wet basis per 100 g), which are present primarily in the form of the isoflavones, daidzein and genistein. Because most naturally occurring phytoestrogens act as selective estrogen receptor modulators, or SERMs, which do not necessarily act as direct agonists of estrogen receptors, normal consumption of foods that contain these phytoestrogens should not provide sufficient amounts to elicit a physiological response in humans. The major product of daidzein microbial metabolism is equol. Only 33% of Western Europeans have a microbiome that produces equol, compared to 50–55% of Asians. Soy isoflavones—polyphenolic compounds that are also produced by other legumes like peanuts and chickpeas—are under preliminary research. As of 2016, no cause-and-effect relationship has been shown in clinical research to indicate that soy isoflavones lower the risk of cardiovascular diseases.
Banting House features archival materials, artifacts, and other ephemera associated with Banting as co-discoverer of insulin, doctor, and artist, as well as his involvement in the first and second world wars. One gallery depicts the kind of office Banting might have had, and contains several of his belongings, including his original medicine cabinet, and a graduated cylinder Banting used during his time at the University of Western Ontario. The apothecary in the next room features a sink that Banting installed for his medical practice. Other galleries in the museum hold original belongings of Banting as well, most notably his desk and his bed frame. The bed frame is kept in Banting's bedroom, and visitors are encouraged to take a moment or a picture with it, as it is not roped off like many other areas of the museum. Additionally, an official replica of the Nobel Prize medal co-awarded to Banting and Macleod is on display, as well as many of Banting's other medals. Other displays include the military gallery, which includes a representation of the type of operating room Banting would have worked in on the field during the First World War, some information on the projects he headed during the Second World War, and an entire gallery filled with artwork done by Banting.
A recent review article attributes these pathological states are caused by lower concentrations of protein and neurotransmitter synthesis within the central nervous system, as well as toxicity due to the buildup of branched-chain amino acids (BCAA) and branched-chain alpha-keto acid (BCKA). There are multiple mechanisms theorized for MSUD encephalopathy.
Sources: en.wikipedia.org
=== Blue Men of Lurgan === The "blue men of Lurgan" were a pair of Lurgan men suffering from what was described as "familial idiopathic methemoglobinemia" who were treated by James Deeny in 1942. Deeny, who would later become the Chief Medical Officer of the Republic of Ireland, prescribed a course of ascorbic acid and sodium bicarbonate. In case one, by the eighth day of treatments, there was a marked change in appearance, and by the twelfth day of treatment, the patient's complexion was normal. In case two, the patient's complexion reached normality over a month-long duration of treatment.
ATC code H01 Pituitary and hypothalamic hormones and analogues is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup H01 is part of the anatomical group H Systemic hormonal preparations, excluding sex hormones and insulins. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QH01. ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version. H01AA01 Corticotropin H01AA02 Tetracosactide H01AB01 Thyrotropin alfa H01AC01 Somatropin H01AC02 Somatrem H01AC03 Mecasermin H01AC04 Sermorelin H01AC05 Mecasermin rinfabate H01AC06 Tesamorelin H01AC07 Somapacitan H01AC08 Somatrogon H01AC09 Lonapegsomatropin H01AX01 Pegvisomant QH01AX90 Capromorelin
=== Music === The game's original score was composed and produced by Rik Schaffer. Troika licensed many songs for the game, and posters for real bands are featured on the walls of the game's clubs. The soundtrack was released as a limited edition CD to customers who pre-ordered the game through Best Buy. It features nine tracks by artists including Daniel Ash, Chiasm, Tiamat, Darling Violetta, Genitorturers, and Lacuna Coil. "Bloodlines", performed by Al Jourgensen and Ministry, was composed and performed specifically for the game. Activision chose the licensed tracks without input from Troika. The song "Angel" by Massive Attack was used as a placeholder on the game's menu screen. Troika could not obtain the rights to use the song in the finished game and tasked Schaffer with creating something similar.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.